Hollister L E, Lombrozo L, Huang C C
Harris County Psychiatric Centre, Houston, Texas 77225.
Int Clin Psychopharmacol. 1987 Jan;2(1):77-82. doi: 10.1097/00004850-198701000-00007.
Plasma concentrations of thiothixene were measured during treatment of 42 treatment-resistant schizophrenic patients. Inter-individual variability was marked even when patients were treated with the same dose or dose regimen. Intra-individual variability was less but still considerable. A highly significant correlation was found between dose and plasma concentration, but this relationship was unpredictable for individual patients. A median plasma concentration of 12 to 15 ng/ml might be expected with daily doses of 60 mg. No definite range of therapeutic plasma concentrations could be determined. Patients who attained moderate degrees of improvement did so at a median dose of 26 ng/ml, which is within the range of therapeutic plasma concentrations previously reported for thiothixene in similar patients.
在对42例难治性精神分裂症患者的治疗过程中，测定了硫利达嗪的血浆浓度。即使患者接受相同剂量或给药方案治疗，个体间差异仍很显著。个体内差异较小，但仍相当可观。发现剂量与血浆浓度之间存在高度显著的相关性，但这种关系对个体患者而言是不可预测的。每日剂量60毫克时，预计血浆浓度中位数为12至15纳克/毫升。无法确定明确的治疗性血浆浓度范围。病情获得中度改善的患者，血浆浓度中位数为26纳克/毫升，这在先前报道的硫利达嗪治疗类似患者的治疗性血浆浓度范围内。
